PMID- 36000281
OWN - NLM
STAT- MEDLINE
DCOM- 20221031
LR  - 20230129
IS  - 1521-0391 (Electronic)
IS  - 1055-0496 (Linking)
VI  - 31
IP  - 6
DP  - 2022 Nov
TI  - Assessing the quality of publicly available videos on MDMA-assisted psychotherapy 
      for PTSD.
PG  - 502-507
LID - 10.1111/ajad.13325 [doi]
AB  - BACKGROUND AND OBJECTIVES: Patients increasingly rely on the Internet for 
      healthcare information. This study aimed to evaluate the quality of videos on 
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic 
      stress disorder (PTSD) on YouTube. METHODS: YouTube was searched for the terms 
      "MDMA" and "PTSD." The 100 most viewed videos were analyzed using three standard 
      quality measures: Global Quality Scores (GQS), JAMA benchmark, and DISCERN. 
      Viewer engagement features and source of upload, video duration, inclusion of 
      patient narrative and/or MD/DO/PhD, the mention of lack of Food and Drug 
      Administration (FDA) approval, side effects, potential for abuse, and use in 
      conjunction with psychotherapy were recorded. RESULTS: The videos were of poor 
      quality (mean GQS: 2.26 +/- 0.94/5, JAMA: 1.96 +/- 0.45/4, and DISCERN: 
      29.5 +/- 8.2/80). A significant positive association was found between video 
      quality and duration (GQS: r = .5857, p < .0001, JAMA: r = .279, p = .0409, 
      DISCERN: r = .5783, p < .0001). Videos including an MD/DO/PhD had the highest 
      scores (GQS: 2.87/5 [1.22], p = .006, DISCERN: 38.35/80 [13.32], p < .0003). A 
      minority of videos were uploaded by academic institutions (1%); most were from 
      professional organizations (29%). No correlation was found between quality and 
      viewer engagement features-number of views, subscribers, likes/dislikes, or 
      comments. A majority mentioned that MDMA must be used in conjunction with 
      psychotherapy (85%) and is not FDA-approved (82%) for PTSD. Only 32% of videos 
      mentioned risks or potential for abuse. CONCLUSIONS: These findings highlight the 
      need for better quality of online health material and an opportunity for 
      involvement of healthcare professionals in the dissemination of accurate health 
      information via content creation. SCIENTIFIC SIGNIFICANCE: This is the first 
      study to examine publicly available information on the use of MDMA for PTSD.
CI  - (c) 2022 American Academy of Addiction Psychiatry.
FAU - Kyarunts, Mariam
AU  - Kyarunts M
AD  - Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Mansukhani, Meghna P
AU  - Mansukhani MP
AD  - Department of Family Medicine, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Loukianova, Larissa L
AU  - Loukianova LL
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
FAU - Kolla, Bhanu P
AU  - Kolla BP
AUID- ORCID: 0000-0001-6627-2410
AD  - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
LA  - eng
PT  - Journal Article
DEP - 20220824
PL  - England
TA  - Am J Addict
JT  - The American journal on addictions
JID - 9208821
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - United States
MH  - Humans
MH  - *Social Media
MH  - Video Recording
MH  - *Stress Disorders, Post-Traumatic/therapy
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/therapeutic use
MH  - Psychotherapy
MH  - Reproducibility of Results
EDAT- 2022/08/25 06:00
MHDA- 2022/11/01 06:00
CRDT- 2022/08/24 03:53
PHST- 2022/06/28 00:00 [revised]
PHST- 2022/03/21 00:00 [received]
PHST- 2022/08/01 00:00 [accepted]
PHST- 2022/08/25 06:00 [pubmed]
PHST- 2022/11/01 06:00 [medline]
PHST- 2022/08/24 03:53 [entrez]
AID - 10.1111/ajad.13325 [doi]
PST - ppublish
SO  - Am J Addict. 2022 Nov;31(6):502-507. doi: 10.1111/ajad.13325. Epub 2022 Aug 24.